Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramelteon + zolpidem
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ramelteon + zolpidem is a combination of two pharmaceutical agents used for the treatment of insomnia. Ramelteon is a melatonin receptor agonist that selectively targets Melatonin receptor type 1 (MT1) and Melatonin receptor type 2 (MT2) in the brain's suprachiasmatic nucleus, thereby regulating circadian rhythms and promoting sleep onset by mimicking endogenous melatonin[5][8]. Zolpidem is a non-benzodiazepine sedative-hypnotic that acts as an agonist at the benzodiazepine site of the Gamma-aminobutyric acid type A receptor (GABAA) complex, enhancing inhibitory neurotransmission to induce sedation and facilitate sleep initiation[6]. Both drugs are approved for short-term management of insomnia but have distinct mechanisms: ramelteon modulates circadian rhythm while zolpidem directly depresses central nervous system activity. The combination may increase risks such as dizziness, drowsiness, confusion, impaired judgment, and motor coordination due to additive CNS depressant effects[1][2].
- Other names
- ramelteon + zolpidem
02
Targets
MTNR1B (Melatonin Receptor 2)GABAA (Gamma-aminobutyric acid receptor)MTNR1A (MT1)
Beyond the preview
Go deeper on ramelteon + zolpidem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramelteon + zolpidem.